Lunit Inc. (KOSDAQ:328130)

Market Cap	1.09T -28.4%
Revenue (ttm)	87.88B +28.8%
Net Income	-67.09B
EPS	-1,518.67
Shares Out	74.38M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	682,337
Open	15,410
Previous Close	14,470
Day's Range	14,630 - 15,740
52-Week Range	13,340 - 30,350
Beta	1.12
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About Lunit

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such a...

• Industry: Software - Application
• Sector: Technology
• Founded: 2013
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 328130

Financial Performance

In 2025, Lunit's revenue was 83.13 billion, an increase of 53.43% compared to the previous year's 54.18 billion. Losses were -47.39 billion, -42.69% less than in 2024.